BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31302075)

  • 41. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma.
    El-Kady NM; Esmat G; Mahmoud EH; Darweesh SK; Mahmoud SH; Elagawy WA
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):628-33. PubMed ID: 23325283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.
    Peng ZW; Zhang YJ; Chen MS; Xu L; Liang HH; Lin XJ; Guo RP; Zhang YQ; Lau WY
    J Clin Oncol; 2013 Feb; 31(4):426-32. PubMed ID: 23269991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.
    Cheng BQ; Jia CQ; Liu CT; Fan W; Wang QL; Zhang ZL; Yi CH
    JAMA; 2008 Apr; 299(14):1669-77. PubMed ID: 18398079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
    Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
    Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.
    Uhlig J; Sellers CM; Stein SM; Kim HS
    Eur Radiol; 2019 May; 29(5):2679-2689. PubMed ID: 30560364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.
    Pompili M; Mirante VG; Rondinara G; Fassati LR; Piscaglia F; Agnes S; Covino M; Ravaioli M; Fagiuoli S; Gasbarrini G; Rapaccini GL
    Liver Transpl; 2005 Sep; 11(9):1117-26. PubMed ID: 16123960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study.
    Choi JW; Lee JM; Lee DH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Cho EJ
    PLoS One; 2020; 15(9):e0239733. PubMed ID: 32986758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases].
    Chen MH; Yan K; Yang W; Gao W; Dai Y; Huo L; Zhang H; Huang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):671-2. PubMed ID: 16378128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiofrequency ablation alone versus radiofrequency ablation combined with chemoembolization in unresectable hepatocellular carcinoma.
    Siriapisith T; Siwasattayanon P; Tongdee T
    J Med Assoc Thai; 2012 Mar; 95(3):430-6. PubMed ID: 22550844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1-5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study.
    Chen S; Peng Z; Lin M; Chen Z; Hu W; Xie X; Liu L; Qian G; Peng B; Li B; Kuang M
    Eur Radiol; 2018 Sep; 28(9):3651-3660. PubMed ID: 29600474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
    Giorgio A; Merola MG; Montesarchio L; Merola F; Santoro B; Coppola C; Gatti P; Amendola F; DI Sarno A; Calvanese A; Matteucci P; Giorgio V
    Anticancer Res; 2016 Nov; 36(11):6179-6183. PubMed ID: 27793949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone.
    Kim JH; Kim PN; Won HJ; Shin YM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.
    Mazzaferro V; Battiston C; Perrone S; Pulvirenti A; Regalia E; Romito R; Sarli D; Schiavo M; Garbagnati F; Marchianò A; Spreafico C; Camerini T; Mariani L; Miceli R; Andreola S
    Ann Surg; 2004 Nov; 240(5):900-9. PubMed ID: 15492574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
    Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
    Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 58. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy.
    Kim W; Cho SK; Shin SW; Hyun D; Lee MW; Rhim H
    Abdom Radiol (NY); 2019 Jun; 44(6):2283-2292. PubMed ID: 30806742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation.
    Kim SS; Kang TW; Kim M; Lee MW; Cho SK; Paik YH; Kim MJ
    Clin Radiol; 2018 Feb; 73(2):216.e1-216.e8. PubMed ID: 28859852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.
    Akamatsu M; Yoshida H; Obi S; Sato S; Koike Y; Fujishima T; Tateishi R; Imamura M; Hamamura K; Teratani T; Shiina S; Ishikawa T; Omata M
    Liver Int; 2004 Dec; 24(6):625-9. PubMed ID: 15566514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.